Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has agreed to sell its US Priority Review Voucher for a total cash consideration of USD160m.
The voucher was awarded in February 2025 following US Food and Drug Administration approval of VIMKUNYA, the company's chikungunya vaccine for individuals aged 12 and older.
Under a licence agreement tied to the 2023 acquisition of the vaccine, the National Institutes of Health will receive 20% of the gross proceeds from the sale of the PRV.
The income will be booked as other operating income, leaving 2025 revenue guidance unchanged. However, EBITDA will see a positive impact, and Bavarian Nordic plans to update its EBITDA margin guidance of 26-30% following the transaction's closing.
The deal is subject to customary closing conditions, including anti-trust review, with completion expected in the third quarter of 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval